#Short-Acting Insulin Market Size

[colinwilson11]

The Short-Acting Insulin Market To Grow At Highest Pace Owing To Increasing Prevalence Of Diabetes

The short-acting insulin market comprises human insulin, insulin lispro, insulin aspart, and insulin glulisine. Short-acting insulin helps patients with diabetes to manage their blood sugar level within a few hours after injection. It is commonly used before or during meals or when blood sugar level is high. The increasing prevalence of diabetes worldwide has significantly boosted the demand for short-acting insulin for effective management and treatment of the disease.

The Short-Acting Insulin Market is estimated to be valued at US$ 9.5 Bn in 2024 and is expected to exhibit a CAGR of 5.1% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the short-acting insulin are Eli Lilly and Company, Novo Nordisk, Sanofi, Biocon, and Adocia.

Eli Lilly and Company is a global leader in diabetes care with prominent products such as Humalog and Admelog. Novo Nordisk is one of the leading pharmaceutical companies in diabetes care with short-acting insulin products such as NovoRapid and Fiasp.

The growing incidence of diabetes due to obesity, lack of physical activity, and unhealthy lifestyles has spurred the demand for short-acting insulin worldwide. According to the International Diabetes Federation, approximately 537 million adults were living with diabetes in 2021, and the number is expected to rise to 643 million by 2030 and 784 million by 2045.

Technological advancements in drug delivery systems have led to the development of novel short-acting insulin formulations for improved efficacy and patient compliance. For instance, Fiasp by Novo Nordisk is an ultra-fast-acting insulin aspart indicated for adults with diabetes.

Market Trends

Growing popularity of pre-filled insulin pens - Pre-filled insulin pens offer convenience of use and accurate dose delivery compared to vials and syringes. This is encouraging more patients and healthcare providers to shift from conventional vials to pre-filled insulin pens.

Growing demand for human insulin analogs - Second-generation human insulin analogs mimicking rapid-acting insulin have demonstrated faster absorption and onset of action. Hence, they are gaining traction over conventional human insulins.

Market Opportunities

Smart insulin delivery devices - Integration of connectivity features in insulin pumps and pens can help synchronize insulin delivery with daily activities and meals. This represents a lucrative avenue.

Emerging economies in Asia - Countries like China, India, Indonesia, and Vietnam are expected to fuel future demand growth owing to increasing diabetes prevalence and enhanced access to treatment options.

In conclusion, the Short-Acting Insulin Market is expected to grow notably in the forecast period owing to the rising prevalence of diabetes worldwide along with technological developments for convenient and more efficient insulin therapies.

Impact Of COVID-19 On Short-Acting Insulin Market Growth

The COVID-19 pandemic has significantly impacted the growth of the Short-Acting Insulin Market. During the initial months of the pandemic, several nations imposed strict lockdowns and social distancing measures to curb the spread of the virus. This led to disruptions across the healthcare sector and supply chain networks. Many diabetic patients faced challenges in regularly accessing insulin therapy and management services during this period. It became difficult for patients to physically visit hospitals or clinics for insulin injections or consultations with doctors. Telehealth and remote monitoring emerged as viable options to ensure continuity of care. However, not all patients had access to these virtual healthcare platforms.

With lockdowns being gradually lifted in many countries post mid-2020, the short-acting insulin market is recovering. Healthcare systems have implemented new protocols and guidelines to minimize infection risks while delivering services. Insulin manufacturers ramped up production to meet any surge in demand. Governments also focused on strengthening supply chains and ensuring uninterrupted availability of diabetes treatment and management products. The COVID-19 pandemic highlighted the need for innovative insulin delivery methods like pens, pumps and wearable devices. It also emphasized the importance of personalized therapy and glucose monitoring technology. In the coming years, the market is expected to grow backed by increasing diagnosis rates, growing awareness about diabetes self-management, and advances in insulin therapy products.

Geographical Regions With Highest Short-Acting Insulin Market Value

North America represented the largest short-acting insulin market in terms of value in 2024. This is attributed to the rising prevalence of diabetes, growing obesity rates, availability of advanced treatment options and high healthcare spending in the US and Canada. Europe held the second position driven by increasing government focus on noncommunicable diseases and presence of major market players. Asia Pacific is projected to be the fastest growing regional market between 2024-2031 backed by growing awareness, expanding patient reach of key players and rising healthcare investments in countries like China and India.

Fastest Growing Regional Market For Short-Acting Insulin

Asia Pacific is poised to be the fastest growing regional market for short-acting insulin during the forecast period from 2024 to 2031. This can be attributed to factors like rising diabetes prevalence, growing medical expenditures, increasing focus on prevention and management of chronic diseases, improving access to diagnosis and treatment services, and expansion initiatives by leading manufacturers. Furthermore, adoption of technologies like smartphones and smart insulin pens is supporting diabetes care in the region. Asia Pacific countries such as China, India and Indonesia offer lucrative growth opportunities for market players due to rising healthcare infrastructure, surge in medical tourism and rapidly increasing patient pool.

Get more insights on this topic: https://www.trendingwebwire.com/advanced-technologies-are-estimated-to-drive-growth-in-the-short-acting-insulin-market/

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )

What Are The Key Data Covered In This Short-Acting Insulin Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Short-Acting Insulin Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Short-Acting Insulin Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Short-Acting Insulin Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Short-Acting Insulin Market vendors

FAQ’s

Q.1 What are the main factors influencing the Short-Acting Insulin Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Short-Acting Insulin Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Short-Acting Insulin Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[mukeshdalgavev123]

Insulin Market Analysis 2024 Growth, Trends, and Future Outlook

Insulin Market Overview

The Global Insulin Market has seen continuous development in the past couple of years and is anticipated to grow much further during the forecast period. The exploration introduces a total evaluation of the Insulin Market and contains Future patterns, Current Growth Factors, mindful sentiments, certainties, chronicled information, and factually bolstered and industry-approved market information.

According to Straits Research, the global Insulin market size was valued at USD 19.94 Billion in 2022. It is projected to reach from USD XX Billion in 2023 to USD 22.20 Billion by 2031, growing at a CAGR of 1.2% during the forecast period (2023–2031).

After identifying promising candidates, they undergo extensive testing and optimization to enhance their effectiveness, safety, and pharmacokinetic properties. This entire process of Insulin Market may take several years and necessitates collaboration between scientists from diverse fields such as chemistry, biology, and pharmacology. Irrespective of the challenges encountered during Insulin Market, it has the potential to revolutionize lives by providing new treatments for various diseases.

Request Sample Report of Global Insulin Market @ https://straitsresearch.com/report/insulin-market/request-sample

Competitive Analysis

The report contains an in-depth analysis of the vendor’s profile, including financial health, business units, key business priorities, SWOT, strategies, and views.

Eli Lilly

Novo Nordisk

Biocon

Sanofi Aventis

Wockhardt

Julphar

GSK and SemBioSys.

The vendors have been identified based on the portfolio, geographical presence, marketing & distribution channels, revenue generation, and significant R&D investments.

Request Sample Report of Global Insulin Market @ https://straitsresearch.com/report/insulin-market/request-sample

Vendors across different verticals are planning for high investments in this market, and as a result, the market is expected to grow at an impressive rate in the upcoming years. The key players are adopting various organic and inorganic growth strategies such as mergers & acquisitions, collaboration & partnerships, joint ventures, and a few other strategies to be in a strong position in the global market.

Market Segmentation Analysis

The report provides a wide-ranging evaluation of the market, providing in-depth qualitative insights, historical data, and supportable projections along with the assumptions about the Insulin Market size. The projections featured in the report have been derived using proven research methodologies and assumptions based on the vendor’s portfolio, blogs, white papers, and vendor presentations. Thus, the research report represents every side of the Insulin Market and is segmented on the basis of regional markets, offerings, applications, and end-users.

By Product Type

Short Acting Human Insulin

Intermediate Acting Human Insulin

Long Acting Human Insulin

Fast-Acting Human Insulin

Premixed Human Insulin

By Delivery System

Syringes

Pens

Pens needles

Pumps

By Application

Type II Diabetes,

Type I Diabetes,

Gestational Diabetes

Pre-diabetes

Access Detailed Segmentation @ https://straitsresearch.com/report/insulin-market/segmentation

Regional Analysis for Insulin Market

The regional analysis offers a comprehensive view of the Insulin Market sales and growth across global and country-level markets. It provides volume and market size data by region, with insights into growth trends in countries like the United States, Canada, Germany, France, China, Japan, and more. The analysis also covers major regions such as North America, Europe, Asia-Pacific, South America, and the Middle East & Africa.

Benefits

Insulin Market Industry companies to ensure business continuity with powerful protection by constantly checking the report and representing attractive growth opportunities for the companies. Insulin Market handles all the needs of the operators by allowing them to improve their services and concentrate on their core business. Insulin Market Research aims to increase business agility and reduce operational and capital expenditure with improved technology rollouts and capacity planning. The report discusses service types and regions related to this Insulin Market. Further, the report provides details about the major challenges affecting the market growth.

Buy Now: https://straitsresearch.com/buy-now/insulin-market

Other Features of the Report:

Provides a thorough analysis of the key strategies with a focus on the corporate structure, R&D methods, localization strategies, production capabilities, sales, and performance in various companies.

Provides valuable insights into the product portfolio, including product planning, development, and positioning.

Thanks for reading this article; you can also get individual chapter-wise sections or region-wise report versions like North America, Europe, or Asia.

About Us:

StraitsResearch.com is a leading research and intelligence organization, specializing in research, analytics, and advisory services along with providing business insights & research reports.

Contact Us: Email: sales@straitsresearch.com Website: https://straitsresearch.com/

[marketinsight1234]

Global Human Insulin Market Size Expected To Reach USD 79100 Million With CAGR 7.90% By 2030

The Global Human Insulin Market size was reasonably estimated to be approximately USD 43000 Million in 2023 and is poised to generate revenue over USD 79100 Million by the end of 2030, projecting a CAGR of around 7.90% from 2023 to 2030.

The human insulin market is a crucial segment of the global pharmaceutical industry, primarily driven by the rising prevalence of diabetes. Human insulin is a synthetic form of the hormone that regulates blood sugar levels in the human body, making it a vital component for individuals suffering from diabetes. This market encompasses various forms of human insulin, including rapid-acting, short-acting, intermediate-acting, and long-acting insulins, all of which are essential for managing diabetes. The global human insulin market has experienced steady growth over the years, with an increasing number of patients seeking effective diabetes management solutions.

Leading players involved in the Human Insulin Market include:

"Novo Nordisk (Denmark), Eli Lilly and Company (US), Sanofi (France), Merck & Co. Inc. (US), Pfizer Inc. (US), Biocon Limited (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), Gan & Lee Pharmaceuticals (China), Julphar (UAE), Bristol-Myers Squibb (US), Takeda Pharmaceutical Company Limited (Japan), Biodel Inc. (US), Oramed Pharmaceuticals Inc. (US), Adocia (France), Tonghua Dongbao Pharmaceutical Co. Ltd. (China), Bioton S.A. (Poland), Torrent Pharmaceuticals Ltd. (India), Lupin Limited (India), B. Braun Melsungen AG (Germany) and Other Major Key Players." 

“Customize Your Solution That Fit Within the Constraints of Your Annual Budget...!”

Get Sample Report: -

Updated Version 2023 is available our Sample Report May Includes the:

Scope For 2023

Brief Introduction to the research report.

Table of Contents (Scope covered as a part of the study)

Top players in the market

Research framework (structure of the report)

Research methodology adopted by Worldwide Market Reports

Market Driver:

One of the key drivers of the human insulin market is the escalating incidence of diabetes worldwide. The prevalence of diabetes, both type 1 and type 2, has been on the rise due to factors such as sedentary lifestyles, poor dietary habits, and genetic predisposition. This has led to a growing demand for insulin products, making it a critical driver for the market. Additionally, advancements in healthcare infrastructure, increased awareness about diabetes management, and the expansion of healthcare services into emerging markets have further fueled the demand for human insulin. As a result, pharmaceutical companies are continually investing in research and development to develop more effective and innovative insulin products to cater to the diverse needs of diabetic patients.

Market Opportunity:

An important market opportunity within the human insulin segment lies in the development of technologically advanced insulin delivery systems. Traditional methods of insulin administration, such as injections, are often associated with discomfort and adherence issues. There is a growing demand for more patient-friendly and efficient insulin delivery methods, including wearable insulin pumps and inhalable insulin options. Developing and commercializing such innovative delivery systems offers a substantial opportunity for companies operating in the human insulin market. By offering convenient, non-invasive, and user-friendly options, manufacturers can tap into a market segment looking for improved patient experience and adherence to insulin therapy.

If You Have Any Query Human Insulin Market Report, Visit:

Segmentation of Human Insulin Market:

By Product Type

Short-Acting

Intermediate-Acting

Long-Acting

Rapid-Acting

Premixed

By Method

Injections

Pumps

Inhalable

By End Users

Hospitals & Clinics

Retail Pharmacies

Online Pharmacies

Diabetes Clinics

By Sales Channel

Online

Offline

An in-depth study of the Human Insulin industry for the years 2023–2030 is provided in the latest research. North America, Europe, Asia-Pacific, South America, the Middle East, and Africa are only some of the regions included in the report's segmented and regional analyses. The research also includes key insights including market trends and potential opportunities based on these major insights. All these quantitative data, such as market size and revenue forecasts, and qualitative data, such as customers' values, needs, and buying inclinations, are integral parts of any thorough market analysis.

Market Segment by Regions: -

North America (US, Canada, Mexico)

Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)

Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)

Asia Pacific (China, India, Japan, South Korea, Malaysia, Thailand, Vietnam, The Philippines, Australia, New Zealand, Rest of APAC)

Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)

South America (Brazil, Argentina, Rest of SA)

Effective Points Covered in Human Insulin Market Report: -

Details Competitor analysis with accurate, up-to-date demand-side dynamics information.

Standard performance against major competitors.

Identify the growth segment of your investment.

Understanding most recent innovative development and supply chain pattern.

Establish regional / national strategy based on statistics.

Develop strategies based on future development possibilities. 

Purchase This Reports: -

About Us:

We are technocratic market research and consulting company that provides comprehensive and data-driven market insights. We hold the expertise in demand analysis and estimation of multidomain industries with encyclopedic competitive and landscape analysis. Also, our in-depth macro-economic analysis gives a bird's eye view of a market to our esteemed client. Our team at Pristine Intelligence focuses on result-oriented methodologies which are based on historic and present data to produce authentic foretelling about the industry. Pristine Intelligence's extensive studies help our clients to make righteous decisions that make a positive impact on their business. Our customer-oriented business model firmly follows satisfactory service through which our brand name is recognized in the market.

Contact Us:

Office No 101, Saudamini Commercial Complex,

Right Bhusari Colony,

Kothrud, Pune,

Maharashtra, India - 411038 (+1) 773 382 1049 +91 - 81800 - 96367

Email: sales@pristineintelligence.com

[123567-9qaaq9]

Informative Report on “Synthetic Peptide Hormones Market ” | Bis Research

Synthetic hormones are artificially created compounds that mimic the actions of naturally occurring hormones in the body. These hormones are designed to interact with specific receptors in cells, triggering biological responses similar to those initiated by naturally produced hormones..

The Synthetic Hormones market size was estimated at $19.40 billion in 2023 and is expected to reach $38.08 billion by 2033, growing at a CAGR of 6.98% during the forecast period 2023-2033. 

Synthetic Peptide Hormones Overview 

Synthetic peptide hormones are artificially produced compounds that mimic the structure and function of naturally occurring peptide hormones in the body. Peptide hormones are short chains of amino acids that act as chemical messengers, regulating various physiological processes by binding to specific receptors on target cells.

hese synthetic peptides are typically created through chemical synthesis techniques, which allow for precise control over their structure and activity. 

Visit our sample page click here ! 

Market Segmentation:

Segmentation 1: by Product Type

Segmentation 2: by Route of Administration

Segmentation 3: by Application

Segmentation 4: by End User

Segmentation 5 : by Region 

Uses of Synthetic Peptide Hormones 

Most commonly used in Hormone Replacement Therapy (HRT) - used to supplement or replace hormones that are deficient or imbalanced in the body. 

Synthetic Hormones can also be used as contraceptives to prevent pregnancy. Birth control pills, patches, injections, and implants contain synthetic versions of estrogen and/or progesterone that work by suppressing ovulation, thickening cervical mucus to prevent sperm from reaching an egg, and thinning the uterine lining to discourage implantation.

Synthetic Hormones are also employed in agriculture to enhance livestock growth and improve milk production

Key Players in the Synthetic Hormones Market 

Eli Lilly and Company Ferring B.V. Bayer AG Pfizer Inc. Novo Nordisk A/S Ipsen Pharma Novartis AG

Have a look at our Life Sciences and Biopharma page click here !

Key Drivers and Trends

Aging Population 

Rising Prevalence of Hormonal Disorders

Increasing Awareness and Acceptance 

Consumer Preferences 

The peptide hormones segment dominated the global synthetic hormones market (by product type) in 2022. The dominance of peptide hormones in the global synthetic hormones market, categorized by type, and the increasing prevalence of chronic diseases such as diabetes, which often requires insulin therapy (a peptide hormone), has led to significant demand for these treatments

Key Questions Answers 

Q What are the major market drivers, restraints, and opportunities within the global synthetic hormones market?

QWhat are the major trends adopted by the global synthetic hormones market?

Q What are the key strategies adopted by key players in the global synthetic hormones market?

Q  How is each product type of segment of the global synthetic hormones market expected to grow during the forecast period 2023-2033?

Q   How is each application segment of the global synthetic hormones market expected to grow during the forecast period 2023-2033?

Q  How is each end user segment of the global synthetic hormones market expected to grow during the forecast period 2023-2033?

Conclusion 

The synthetic peptide hormones market is poised for significant growth driven by increasing research and development activities, expanding applications across various therapeutic areas, and rising demand for personalized medicine. 

With advancements in peptide synthesis technologies, growing investments in biotechnology and pharmaceutical sectors, and evolving regulatory landscapes, the market is witnessing a surge in innovation and commercialization of peptide-based therapies.

The future of the synthetic peptide hormones market appears promising, with continued focus on research, innovation, and strategic collaborations poised to unlock further growth opportunities and address unmet medical needs.

[lalsingh228-blog]

Anti-diabetic Medication Market is Set To Fly High in Years to Come

Global Anti-diabetic Medication Market Report from AMA Research highlights deep analysis on market characteristics, sizing, estimates and growth by segmentation, regional breakdowns & country along with competitive landscape, player’s market shares, and strategies that are key in the market. The exploration provides a 360° view and insights, highlighting major outcomes of the industry. These insights help the business decision-makers to formulate better business plans and make informed decisions to improved profitability. In addition, the study helps venture or private players in understanding the companies in more detail to make better informed decisions. Major Players in This Report Include, AstraZeneca plc (United Kingdom), Bayer AG (Germany), C.H. Boehringer Sohn AG & Ko. KG (Germany), Bristol-Myers Squibb (United States), Eli Lilly (United States), Halozyme Therapeutics (United States), Johnson & Johnson (United States), Merck & Co. Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States). Free Sample Report + All Related Graphs & Charts @: https://www.advancemarketanalytics.com/sample-report/162818-global-anti-diabetic-medication-market Anti-diabetic medications are medicines developed to stabilize and control blood glucose levels amongst people with diabetes. Anti-diabetic medications are commonly used to manage diabetes. Anti-diabetic medications are all pharmacological agents that have been approved for hyperglycemic treatment in diabetes mellitus. The increasing prevalence of diabetes across the globe will stimulate the market potential for anti-diabetic medication during the forecast period. Market Drivers

Rising Prevalence of Chronic Diseases like Diabetes across the Globe

Growing Prevalence of Lifestyle-Induced Disorders such as Obesity

Market Trend

Increasing Adoption of Oral Antidiabetic Drugs

Opportunities

Rising Spending on Research and Development for Innovative Drugs

Challenges

Safety Issues Pertaining to Some Diabetic Drugs

Enquire for customization in Report @: https://www.advancemarketanalytics.com/enquiry-before-buy/162818-global-anti-diabetic-medication-market In this research study, the prime factors that are impelling the growth of the Global Anti-diabetic Medication market report have been studied thoroughly in a bid to estimate the overall value and the size of this market by the end of the forecast period. The impact of the driving forces, limitations, challenges, and opportunities has been examined extensively. The key trends that manage the interest of the customers have also been interpreted accurately for the benefit of the readers. The Anti-diabetic Medication market study is being classified by Type (Insulin (Rapid acting analog, Long-acting analog, Premixed insulin, Short-acting analog, and Intermediate-acting insulin), Drug class (Alpha glucosidase inhibitors, Biguanides, Sulphonylureas, GLP-1 (Glucagon-like peptide) agonists, DPP-IV (Dipeptidyl Peptidase) inhibitors, Meglitinides, SGLT-II (Sodium-Glucose Transport Proteins) inhibitors, and Thiazolidinedione)), Application (Prevent and Treatment Diabetes, Obesity Treatment, Cardiovascular Protection, Others), Route of Administration (Insulin Syringe/ Insulin Pen, Insulin Pump, Intravenous Infusion, Oral, Others), End User (Pediatric, Adult, Geriatric) The report concludes with in-depth details on the business operations and financial structure of leading vendors in the Global Anti-diabetic Medication market report, Overview of Key trends in the past and present are in reports that are reported to be beneficial for companies looking for venture businesses in this market. Information about the various marketing channels and well-known distributors in this market was also provided here. This study serves as a rich guide for established players and new players in this market. Get Reasonable Discount on This Premium Report @ https://www.advancemarketanalytics.com/request-discount/162818-global-anti-diabetic-medication-market Extracts from Table of Contents Anti-diabetic Medication Market Research Report Chapter 1 Anti-diabetic Medication Market Overview Chapter 2 Global Economic Impact on Industry Chapter 3 Global Market Competition by Manufacturers Chapter 4 Global Revenue (Value, Volume*) by Region Chapter 5 Global Supplies (Production), Consumption, Export, Import by Regions Chapter 6 Global Revenue (Value, Volume*), Price* Trend by Type Chapter 7 Global Market Analysis by Application ………………….continued This report also analyzes the regulatory framework of the Global Markets Anti-diabetic Medication Market Report to inform stakeholders about the various norms, regulations, this can have an impact. It also collects in-depth information from the detailed primary and secondary research techniques analyzed using the most efficient analysis tools. Based on the statistics gained from this systematic study, market research provides estimates for market participants and readers. Contact US : Craig Francis (PR & Marketing Manager) AMA Research & Media LLP Unit No. 429, Parsonage Road Edison, NJ New Jersey USA – 08837 Phone: +1 201 565 3262, +44 161 818 8166 sales@advancemarketanalytics.com

[mrfr-blogs]

Analyzing the Size and Scope of Human Insulin Market Industry

Market Overview –

The Human Insulin Market is witnessing steady growth driven by the increasing prevalence of diabetes worldwide and the growing demand for insulin therapy. Human insulin, a synthetic form of the hormone produced by the pancreas, is widely used for managing diabetes mellitus, a chronic condition characterized by elevated blood sugar levels.

Key factors contributing to market growth include rising obesity rates, sedentary lifestyles, and an aging population, which are major risk factors for developing type 2 diabetes. Additionally, advancements in insulin delivery devices, such as insulin pens, pumps, and inhalers, enhance convenience and adherence to insulin therapy, further fueling market expansion.

The market offers a wide range of human insulin products, including rapid-acting, short-acting, intermediate-acting, and long-acting insulin analogs, catering to diverse patient needs and treatment regimens.

The Human Insulin market, driven by the widespread prevalence of diabetes, is witnessing steady growth. Insulin recombinant products play a pivotal role in managing blood sugar levels for individuals with diabetes. With increasing awareness and demand for effective diabetes management, the market for human insulin, particularly recombinant variants, continues to expand globally.

Furthermore, favorable reimbursement policies, increasing healthcare expenditure, and growing awareness about diabetes management drive market growth. Moreover, the COVID-19 pandemic has underscored the importance of managing chronic conditions like diabetes, leading to heightened focus on insulin therapy and related products.

Despite the market's positive outlook, challenges such as insulin affordability, access to healthcare services, and concerns about hypoglycemia and weight gain associated with insulin therapy may hinder market growth. Nonetheless, ongoing research and development efforts aimed at developing innovative insulin formulations and delivery methods hold promise for addressing these challenges and sustaining market expansion in the foreseeable future.

The size of the human insulin market was estimated at USD 1.93 billion in 2022 and is expected to increase at a compound annual growth rate (CAGR) of 4.9% between 2023 and 2032, from USD 1.98 billion in 2023 to USD 2.81 billion.

Segmentation –

The global human insulin market has been segmented based on type, methods, indication, and end users. By type, the market has been segmented into accessories and devices. By methods, the market has been segmented into traditional human insulin and modern human insulin. By indication, the market has been segmented into type 1 diabetes and type 2 diabetes. By end users, the market has been segmented into hospitals, forensic laboratories, research centers, and others.

Regional Analysis –

The Human Insulin Market exhibits diverse regional trends influenced by factors such as healthcare infrastructure, regulatory policies, and diabetes prevalence. North America leads the market, driven by a high incidence of diabetes, advanced healthcare facilities, and a well-established pharmaceutical industry.

The region boasts a significant market share due to widespread adoption of human insulin products and continuous advancements in diabetes management. Similarly, Europe holds a prominent position in the market, characterized by robust healthcare systems, increasing geriatric population, and favorable reimbursement policies for insulin therapy. Adoption of innovative insulin delivery devices and emphasis on personalized diabetes care further contribute to market growth in the region. In Asia Pacific, the market is witnessing rapid expansion fueled by rising diabetes prevalence, increasing awareness about the importance of early diagnosis and treatment, and improving access to healthcare services.

Countries like China and India are driving market growth with their large diabetic populations and growing healthcare expenditure. Latin America and the Middle East & Africa regions present opportunities for market penetration, supported by improving healthcare infrastructure and rising investments in diabetes management programs. However, challenges such as limited access to healthcare resources and affordability issues may impact market growth in these regions. Overall, the Human Insulin Market demonstrates promising growth prospects across diverse regions, driven by the universal need for effective diabetes management solutions.

Key Players –

Human Insulin companies include Adocia, Merck & Co. Inc., Julphar, Pfizer Inc., Bristol-Myers Squibb Company, GlaxoSmithKline Plc, Sanofi, Oramed, Novo Nordisk India Pvt. Ltd., Eli Lilly and Company, Biocon, Tonghua Dongbao Pharmaceutical Co., Ltd., among others.

Related Reports –

Meningitis Diagnosis and Treatment

Endodontic Devices

Fertility Drug and Surgery

Opioids

For more information visit at MarketResearchFuture

[reportsneww]

Human Insulin Market Size 2023 to 2031

Newark, New Castle, USA – Growth Plus Reports’ most recent study examines the Global Human Insulin Market’s production, prospective uses, demand, key companies, and SWOT analysis.

The Human Insulin Market Report will help you determine the best distribution strategies for specific products and identify potential markets. In addition, the report examines the purchasing and supply patterns that impact the market. The Human Insulin market research report provides insights into the limitations, market trends, prospects, drivers, and competition in the Human Insulin sector.

You may get insights into the TOC, and Statistics for essential facts, information, trends, and competitive landscape information.

Download Free Sample Report Now @ https://www.growthplusreports.com/inquiry/request-sample/human-insulin-market/7723

The following are the leading companies in the Global Human Insulin market:

Novo Nordisk A/S

Eli Lilly and Company

Sanofi S.A.

Biocon Ltd

Wockhardt Limited

GSK plc

Julphar

Bioton S.A

Merck & Co., Inc.

Tonghua Dongbao Pharmaceutical

Growth Plus Reports studies the key trends in each category and sub-segment of the Human Insulin market, along with Global and regional projections from 2023 to 2031. Our research splits the market into product type and application segments.

SEGMENTATION

GLOBAL HUMAN INSULIN MARKET – ANALYSIS & FORECAST, BY DRUGS

Biosimilars

Rapid Acting

Long Acting

Premixed

Biologics

Short Acting

Intermediate Acting

Premixed

GLOBAL HUMAN INSULIN MARKET – ANALYSIS & FORECAST, BY APPLICATION

Type 1 Diabetes 

Type 2 Diabetes

GLOBAL HUMAN INSULIN MARKET – ANALYSIS & FORECAST, BY DISTRIBUTION CHANNEL

Retail Pharmacies

Hospital Pharmacies

Online Pharmacies

For More Information or Query or Customization visit: https://www.growthplusreports.com/inquiry/customization/human-insulin-market/7723

Companies may utilize Human Insulin market report to get insights on market variables and any restraints that may affect the manufacturing of their product. Companies that are expanding abroad require thorough Global market research that includes real market data to assist with their marketing strategy. This Global market Human Insulin industry study analyzes important market dynamics and provides in-depth information and statistics to help companies flourish. This research report on the Human Insulin market takes advantage of advanced and professional approaches such as SWOT analysis and GRG Health’s unique GrowthMIX strategy.

This report is useful in addressing various essential issues for market participants, while also supporting them in making investments and leveraging the market opportunities.

Human Insulin Market TOC: https://www.growthplusreports.com/report/toc/human-insulin-market/7723

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

QUICK BUY: https://www.growthplusreports.com/checkout-7723

Browse Latest Healthcare Reports:

Brain Metastasis Therapeutics Market

Cognitive Assessment and Training in Healthcare Market

Frontotemporal Dementia Treatment Market

Hair Care Market Hypercholesterolemia Treatment Market

Injectable Cytotoxic Drugs Market

Mononucleosis Diagnostics Market

Niemann-Pick Disease Market

Vertebral Compression Fracture Devices Market

[automotiveera]

What are Different Types of Insulin Delivery Devices?

The first factory-made insulin pump was back in 1975 and the first insulin pen was introduced in 1985. From then on, numerous improvements have been done in the field of insulin devices. Pens, in comparison to syringes offer better accuracy, patient satisfaction, ease of use, adherence, and quality of life. The U.S. database analyses show that the improved adherence was possible by the usage of an insulin pen, which has the capability to decrease the expense of diabetes care as compared to the usage of a vial or a syringe.

Types of Insulin Devices

Syringe

A syringe is a device with a plunger, removable needle guard, and hollow center. The external part of the syringe is marked with lines to assist a person to inject the right amount of insulin.  These are the things to be kept in mind when using a syringe for insulin delivery.

Do not reuse a syringe.

Do not share the syringe with anyone.

Break the needle after use.

Insulin Pen

An insulin pen is a vaccination device, just about the size and shape of a magic marker. It injects insulin into the fatty tissue below the skin usually in the thigh, arm, and stomach through a short, thin disposable needle.

This device is easy to use, just twist or put a new needle, prepare the dose, inject the insulin, and throw away the used needle. 

Insulin Pump

Individuals with diabetes who face trouble in controlling the level of blood sugar by using a pen and syringe can use an insulin pump to inject insulin, as it is a relatively comfortable method. 

This pump is filled with rapid or short-acting insulin. Insulin is dosed before every meal, and there is also a small amount of insulin delivered every 24 hours. The pump calculates how much insulin is required by an individual on the basis of the carbohydrate intake. The pump also helps in preventing overdoses.

The pump is attached to a tube when required. A catheter is fixed on the patient’s abdomen beneath the layers of the skin. Normally The pump is attached to the waist.

Jet Injection

Jet injection devices are for people, afraid of needles. The injector has numerous insulin doses. To manage a dose, an individual just needs to hold the injector on the skin, push a button, and a jet forces insulin via skin. It can bring about bruising. Jet injectors are not that common type of insulin delivery.

Hence, as the number of people suffering from diabetes are increasing extensively, and they are becoming more aware about the usage of insulin delivery devices. Such factors will drive the demand for insulin delivery devices in the future.  

Market Overview @ Insulin Delivery Devices Market Demand Forecast to 2030

[colinwilson11]

The short-acting insulin market has witnessed significant growth over the past few years owing to the rising prevalence of diabetes worldwide. Short-acting insulin helps manage blood glucose levels in diabetes patients immediately after a meal. The most commonly used short-acting insulin products include insulin lispro, insulin aspart, and insulin glulisine. These synthetic insulin analogs work faster as compared to regular human insulin and have a shorter duration of action.

[f107aquaticinvertebrates]

Predatory Snail (Conus)

*hehe will post our next blogpost on the account*

Group 3

I. Classification

Kingdom               Animalia Subkingdom         Bilateria Infrakingdom        Protosomia Superphylum       Lophozoa Phylum                Mollusca Class                   Gastropoda Subclass              Prosobranchia Order                   Neogastropoda Family                  Conidae Genus                  Conus

ITIS (n.d.)

II. Biology

Tropical Dwellers

Approximately, there are 700 Conus species. The majority is found throughout tropical and subtropical waters, such as the South China Sea, Australia, and the Pacific Ocean. Few species were found in South Africa, Southern Australia, Southern Japan, and Mediterranean Sea (Dutertre and Lewis, 2011). There are also existing species thriving in temperate waters such as C. californicus which are found in the North American Pacific coast(Gao et al. 2017).

Figure 1. Worldwide distribution of cone snails. Spot colors stand for various species number (Gao et al. 2017). Image retrieved from:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5744117/#B37-toxins-09-00397

Habitat

Cone snails are commonly found in intertidal and shallow sublittoral zones. They are present in coral reef areas, sand bottoms, and silty crevices. Some were reportedly found in mangrove areas, and in deeper waters of up to 400-600 meters (Carpenter and Niem, 1998; Dutertre and Lewis, 2011). 

Anatomy

Cone snails are gastropods. Gastropods have asymmetrical body symmetry and their shells are spirally coiled. Conus shells are cone-shaped. The spire of the shell is conical and moderately low to flat. It has a well-developed body whorl that tapers towards the narrow anterior end. The aperture is very long and narrow. There is a notch at the aperture’s posterior end, and a short, wide siphonal canal is located at the anterior end. The operculum is corneous, small, and ovate to claw-shaped. However, the operculum may not always be present (Carpenter and Angelis, 2016).

Figure 2. Ventral view of Conus shell with labelled parts.

Image retrieved from:http://www.fao.org/3/a-i5712e.pdf 

The soft body of gastropods has 4 main regions: the head, the foot, the visceral mass, and the mantle. The head protrudes from the anterior end. The foot is a muscular ventral organ with a flattened base used for locomotion (creeping or burrowing). The visceral mass is located in the spire of the shell and contains most organ systems. The mantle is a collar-like tegument which lines and secretes the shell and forms a mantle cavity normally provided with respiratory gills in aquatic species (Carpenter and Angelis, 2016).

Figure 3. Internal anatomy of Conus striatus.

Image retrieved from:https://www.marinelifephotography.com/marine/mollusks/gastropods/cones/cones.htm 

Cone snails have a specialized venom apparatus that comprises a venom gland, salivary glands, a radular sac, a pharynx, a proboscis, and a radula. The radula of the cone snail is hollowed and barbed and it resembles a harpoon. These harpoons are produced and stored in the radular sac, which is divided into two arms and connects to the pharynx. The short arm contains a few fully formed radula while the long arm is where the radulas are produced.

The cone snail uses chemosensory to detect prey. Once the prey is detected, it will extend its proboscis and shoot its radula which will inject a potent venom to paralyze its prey (Kohn et al. 1972; Marsh 1977; Salisbury et al. 2010; Schulz et al. 2004).

Images retrieved from:https://kristinabarclay.wordpress.com/2016/07/

Figure 4. Close-up photo of a cone snail’s radula (top). Cone snail radula under an electron microscope (bottom). 

Life Cycle

Most cone snail species have separate sexes and fertilization happens internally. Cone snails lay their eggs once a year. The egg masses of cone snails are usually made up of up to 25 egg capsules with each capsule containing roughly around 1000 eggs (Zehra & Perveen 1991). Two types of cone snail hatchlings have been described, the veliger stage (free-swimming larvae) and veliconcha stage (juvenile snails). During these stages, only a few will survive. In between 1 and 50 days, the snails will undergo the pelagic stage (Perron, 1983).

According to Rockel et al as cited in Dutertre and Lewis (2011), it is estimated that cone snails have a lifespan of 10-20 years. This estimated lifespan is based on the marks and shell growth of the snail. They can reach a maximum size of > 20 cm, but most species are < 8 cm  and weight < 100 g. 

Figure 5. Conus magus with egg sacs

Image retrieved from:https://poppe-images.com/?t=17&photoid=951805

Figure 6. Conus ammiralis with its egg capsules attached to Halimeda sp. algae.

Images retrieved from:http://www.underwaterkwaj.com/shell/cone/Conus-ammiralis.htm

III. Relationship with Humans

Cone snails are exploited for ornamental trade and research. 

Conus shells have economic value and are marketed as ornaments. One of the rarest and most valuable shells in the world is the Conus gloriamaris or the Glory of the Seas Cone (The Editors of Encyclopaedia Britannica 2020). 

Conantokins or sleeper peptides from the geographic cone snail are short chain peptides that can affect neural receptors in fish and mammals. This peptide has great potential that humans can benefit from when it comes to paint ecpetop, drug and alcohol withdrawal symptoms and learning. Con-G one of the conatokins from the geographic cone snail has been found to act as a neuroprotective agent in brain ischemia from strokes. Conus shells contain conotoxin which is used for drug development. For example, the ω-MVIIA (ziconotide) is a well-known conotoxin approved by the U.S. Food and Drug Administration (2004) to treat chronic pain in cancer and AIDS patients. It is derived from the toxin/venom produced by Conus Magus (Gao et al. 2017). Conus regius is rich in alpha-conotoxins, which can target nicotine receptors and can help in research concerning the development of medicine for Alzheimer’s disease, schizophrenia, lung cancer and even tobacco addiction. (Kompella et al. 2015)

Death by conus?

Humans can be negatively affected by conus. It is recorded that 30 humans have died from a conus sting. Once stung, the victim feels numbness accompanied by dizziness, slurred speech and respiratory paralysis and then death.

IV. Did you know?

1. The venom from one cone snail has a hypothesized potential of killing up to 700 people. (Kapil S., et al.)

2. The Geographic Cone Snail (Conus geographus), according to BBC Earth, is the most toxic cone snail in the world. Its venom contains a protein which when isolated scientists can be used as effectively as a morphine substitute without the harmful side effects. 

3. A person was recorded to be killed from a cone snail sting in as short as 5 minutes!

4. Some cone snails are solitary in nature, like the  Conus spurius or the Alphabet cone, and the only time individuals have contact with each other is during mating!

5. The largest Alphabet cone shell was recorded at 80 mm or as large as your regular sized mountain dew can!

6. Conus species were observed to exhibit “fishermen-like” behavior when hunting for food! They use their proboscis as lures and catch their prey, scientists even coined the term hook and line method to describe this hunting behavior, just like the fishing method.

7. The cone snail is the only recorded species in the animal kingdom to use insulin as a chemical weapon, a hormone that is also used to help diabetic people! Even though this is used as a means to catch prey, scientists actually used insulin from the cone snail’s venom and combined it with human insulin creating a new type of insulin called mini-Ins. 

IV. References

Chivian, E., et. al. (2003, November). The Threat to Cone Snails. Retrieved October 3, 2020 from: https://www.researchgate.net/publication/9046809_The_Threat_to_Cone_Snails_1

Gao B, Peng C, Yang J, Yi Y, Zhang J & Shi Q. 2017. Cone Snails: A Big Store of Conotoxins for Novel Drug Discovery. 2017; 9(12): 397. DOI: 10.3390/toxins9120397

Geography Cone. (2018, September 21). Retrieved October 3, 2020, from https://www.nationalgeographic.com/animals/invertebrates/g/geography-cone/

Hall, M. (n.d.). Conus geographus (geography cone snail). Retrieved October 3, 2020, from https://animaldiversity.org/accounts/Conus_geographus/

Kane, S. (2017, December 4). The most venomous animal on Earth is truly surprising. Retrieved October 3, 2020, from https://www.businessinsider.com/most-venemous-animal-cone-snail-2016-2?international=true&r=US&IR=T

Kohn, A.J. (2016). Human injuries and fatalities due to venomous marine snails of the family Conidae. DOI: 10.5414/CP202630 

Kompella SN, Hung A, Clark RJ, Mari F, Adams DJ. 2015. Alanine Scan of α-Conotoxin RegIIA Reveals a Selective α3β4 Nicotine Acetylcholine Receptore Antagoist. Journal of Biological Chemistry, 2015; 290(2): 1039 DOI: 10.1074/jbc.M114.605592 

Kohn, A.J. (2016). Human injuries and fatalities due to venomous marine snails of the family Conidae. DOI: 10.5414/CP202630 

Safavi-Hemami, J., et. al. (2014). Specialized insulin is used for chemical warfare by fish-hunting cone snails. Proc. Natl. Acad. Sci. U.S.A. 10.1073/pnas.1423857112 (2015).

Sygo, M. (1999). "Conus spurius" (On-line), Animal Diversity Web. Retrieved October 03, 2020 from https://animaldiversity.org/accounts/Conus_spurius/

The Editors of Encyclopaedia Britannica. 2020. Bugs, Mollusks & Other Invertebrates. Retrieved from https://www.britannica.com/animal/cone-shell

Xiong, X., Menting, J.G., Disotuar, M.M. et al.(2020). A structurally minimized yet fully active insulin based on cone-snail venom insulin principles. Nat Struct Mol Biol 27, 615–624 (2020). https://doi.org/10.1038/s41594-020-0430-8

[mcatmemoranda]

Hypoglycemics cause insulin release. Insulin effect is to lower blood glucose, so it can cause hypoglycemia. So sulfonylureas, which increase insulin release, are hypoglycemics.

Response to hypoglycemia is secretion of glucagon. The other response is hypothalamic pituitary system activation of adrenal cortex and secretion of cortisol. Adrenal medulla secretes epinephrine. The epinephrine causes sweating, shaking, tachycardia, palpitations, anxiety, pallor. It’s sympathetic overdrive. When you give a beta blocker (especially non-selective), you mask these symptoms; pts would thus have hypoglycemia and not know it. Sulfonylureas bind to albumin and can displace other protein-bound drugs. If you were on a sulfonylurea and warfarin, warfarin could be displaced from the protein. So they would have increased side effects from warfarin.

Sulfonylureas close the K+ channel, helping with insulin secretion. They cause hypoglycemia, which leads to eating and weight gain. Sulfonylureas have sulfur in them, so if you’re allergic to sulfur, don’t take these.

First generation sulfonylureas are not used much anymore. The pharmacokinetics discourage their use. Chlorpropamide causes a disulfiram-like reaction (metronidazole + EtOH--> blocked aldehyde dehydrogenase--> increased aldehyde). Chlorpropamide + EtOH--> disulfiram-like reaction. Chlorpropamide has some effect on vasopressin secretion (vasopressin = ADH; causes water reabsorption, which can cause hyponatremia).

TCT = Tolazamide, Chlorpropamide, Tolbutamide = first generation sulfonylureas.

Second generation sulfonylureas are the ones more commonly used. Glipizide is less potent and less likely to cause hypoglycemia, which is why it’s preferred in elderly, who are more susceptible to hypoglycemia and can get injuries because they can fall when hypoglycemic. Glimepiride is good for those with renal disease because it’s metabolized not in the kidneys, but in the liver.

GGG = Glyburide, glipizide, glimepiride

Meglitinides don’t have sulfur, but act like sulfonylureas; good for those with sulfa allergies. They work like rapid-acting insulin; short duration of action--> less likely to cause hypoglycemia.

Euglycemic drugs normalize the blood sugar but don’t affect insulin, so they are less likely to cause hypoglycemia (unless of course, you mixed them with a hypoglycemic like a sulfonylurea or meglitinide).

Metformin is firstline for tx of DM2. It's a biguanide euglycemic antidiabetic drug. It decreases gluconeogenesis by activating AMP kinase--> phosphorylation--> decreased hepatic glucose production. The liver decreases FA production--> decreases fatty liver. Metformin can decrease vitamin B12--> macrocytic anemia. In PCOS, there’s insulin resistance. So metformin helps with that. Metformin causes decreased hepatic steatosis and increased insulin sensitivity. It decreases hyperglycemia and plasma TGs.

Metformin’s metabolite can cause lactic acidosis. If you have trouble getting rid of the metabolite or you’re an alcoholic, you can end up with lactic acidosis. When you give contrast dye, there’s a short term decrease in GFR. So you have to stop metformin for several days before the pt goes for imaging that will require contrast. The decreased GFR leads to the metformin metabolites not being excreted, which increases the risk for lactic acidosis.

Metformin inhibits the ETC--> higher levels of NADH, so you need to then make lactate to regenerate NAD+. The lactate--> lactic acidosis. Phenformin is an antidiabetic drug from the biguanide class. It was marketed as DBI by Ciba-Geigy, but was withdrawn from most markets in the late 1970s due to a high risk of lactic acidosis, which was fatal in 50% of cases. Metformin is better, but can still cause lactic acidosis.

The thiazolidinedione/TZD/”-glitazones” agonize PPAR-gamma to increase GLUT4--> glucose uptake into muscle and fat. (Fibrates are PPAR-alpha agonists). Rosiglitazone has never been proven to cause CV events; diabetics are likelier to have CV events anyway.

PPAR-gamma is expressed in the collecting duct of the kidney ENac—epithelial sodium channels. So taking TZD--> increased ENac function--> sodium reabsorption and fluid retention. Amiloride can prevent this. There may be increased osteoclasts with TZDs--> bone fractures, especially in post-menopausal women. Troglitazone = Rezulin; was the first TZD, was withdrawn because it caused acute hepatitis. So if you’re going to start pioglitazone or rosiglitazone, it’s a good idea to do baseline LFTs and to do LFTs regularly. PPAR receptor is in other places. So gestational diabetes is managed with insulin. Inducers = Barbiturates, St. John’s Wort, Carbamazepine, Rifampin, Alcohol (chronic), Phenobarbital, Griseofulvin, Phenytoin, Sulfonylureas; and nevirapine. Inducers of CYP3A4 inducer metabolism of TZDs--> subtherapeutic TZD levels.

Alpha glucosidase is an enzyme on the brush border that breaks down carbs. So alpha glucosidase inhibitors block the enzyme needed to absorb carbs. Carbs stay in the gut--> diarrhea, cramps. Pts with IBS more prone to side effects. If these drugs are combined with insulin, you can get hypoglycemia. Treat hypoglycemia with dextrose.

Pramlintide is an amylin analog; delays gastric emptying--> reduced appetite. Given subQ because proteins are digested if given PO. Never mix pramlintide with insulin. It suppresses glucagon release, manages postprandial hyperglycemia. It can be used in DM1 as well. Can cause hypoglycemia if mixed with insulin.

Exenatide is an incretin used in conjunction with metformin and a TZD. It was isolated from lizard saliva. Dr. Eng at Bronx hospital did studies on it. Exenatide is a GLP-1 analog. GLP-1 is an incretin that comes from L cells of the intestines; suppresses glucagon release, decreases gastric emptying--> satiety; increases pancreatic beta cell mass. That can be a problem (pancreatic CA). Exenatide can help with weight loss (which can be good for diabetics).

“-glutides” = GLP-1 receptor agonists. They can be used 1x a week. Albiglutide binds albumin, so it dissociates slowly. Increased pancreatic beta cell size may make them prone to inflammation/cancer risk--> pancreatitis/pancreatic cancer? GLP increases cAMP in thyroid C cells--> higher risk of medullary thyroid cancer. “-glutides” are given SubQ.

“-gliptins” = Dipeptidyl peptidase 4 inhibitors (DPP-4). DDP-4 breaks down GLP-1. So if we inhibit DDP-4, we will have more GLP-1. These are given orally. DPP-4 is a tumor suppressor. So blocking it--> increased cancer risk. “-giptins” block DPP-4--> higher GLP-1 and its insulin-stimulating effects--> lowered blood glucose.

“-flozin” = “flows in,” so it makes glucose flow into the urine. Perfect mnemonic! In the PCT, the flozins block glucose reabsorption--> glucose is lost in urine. The more glucose they lose in urine, the more UTIs the pt can have.

Hypoglycemia treatment: orange juice with sugar added is good if the pt is conscious and can drink, otherwise give glucagon or dextrose. D50W = dextrose. Glucagon (or dextrose) is given if the hypoglycemic pt is not conscious. Glucagon causes gluconeogenesis in the liver; will increase HR and strength of contraction. Glucagon works like a beta agonist (increases cyclic AMP). Ergo, glucagon is given if a pt overdosed on a beta blocker (because beta blockers--> bradycardia and glucain has positive chronotropic and ionotropic effects--it increases HR and strength of contraction). Glucagon enhances cAMP--> increased AV node. Beta 2 blockade--> bronchoconstriction. Beta 2--> vasoconstriction. Beta 2 block--> block of glycogenolysis. Beta 1 block--> no sympathetic effects of hypoglycemia. So non-selective beta blockers (propranolol)--> masked hypoglycemia. Overdose of CCBs--> no insulin release--> hyperglycemia.

[researchvishal]

Continuous Glucose Monitoring Systems Market Study: An Emerging Hint of Opportunity by 2032

The market for continuous glucose monitoring systems market size  is anticipated to reach a size of US$ 1.1 billion in 2022 and then grow at a CAGR of 10.8% to US$ 3.0 billion by the end of 2032. In 2021, the global continuous glucose monitoring systems market will be dominated by sensors, with a share of around 48.5%, according to a recent analysis by Future Market Insights.

Continuous glucose monitoring systems are adopted by many end-users including household, and hospitals and diagnostics centers. There is an increase in the usage of continuous glucose monitoring systems components in hospitals and diagnostic centers due to an increase in the demand for sensor.

Currently, companies are focusing on continuous development and the introduction of innovative continuous glucose monitoring system devices to receive FDA approval for various brands, which has led to high competitiveness in the market. Scientists are conducting research and testing continuous glucose monitoring systems to provide effective systems and aid better management of diabetes.  Thus, there is scope for the introduction of new and advanced continuous glucose monitoring systems in the near future. Market players operating in the continuous glucose monitoring systems market are focused towards the integration of advanced technologies in products in order to offer variations and trends in the type of blood glucose level display.

On the other hand, the high cost of continuous glucose monitoring systems acts as a restrain for the growth of the market as treatment with continuous glucose monitoring systems costs around US$ 4,930 to US$ 7,120 per person. This makes it unaffordable for a large portion of the global population. For instance, glucose monitors used in continuous glucose monitoring systems cost between US$ 1,000 and US$ 1,400, while sensors cost between US$ 35 and US$ 100 apiece. Besides this, sensors have a very short lifespan – around 3 to 7 days – since they are prone to biofouling, which affects the accuracy of the continuous glucose monitoring systems.

Due to the lack of accuracy in the readings of glucose levels in critical cases, continuous glucose monitors are incapable of preventing severe hypoglycemia stage, in which the glucose level in the body is extremely low. For instance, continuous glucose monitoring systems are up to 21% less accurate when compared with actual plasma glucose values and this percentage increases when there is a rapid rise and fall in plasma glucose. According to the results of studies, it is estimated that the probable reason behind this problem is the real-time performance delay of continuous glucose monitoring systems.

The global continuous glucose monitoring systems market has been categorized on the basis of component into transmitter & monitor, sensor and insulin pump. On the basis of end-use, the continuous glucose monitoring systems market has segmented into household and hospitals and diagnostics centers. In terms of revenue, the household segment dominated the global continuous glucose monitoring systems market. Hospital and diagnostics centers segments are anticipated to expand at the fastest CAGRs over the forecast period.

This continuous glucose monitoring systems report also covers trends that drive each segment and offers analysis & insights regarding the potential of the continuous glucose monitoring systems market in regions such as North America, Latin America, Western Europe, Eastern Europe, APEJ, Japan, Middle East & Africa, and Japan. Among these regions, the APEJ continuous glucose monitoring systems market is projected to exhibit relatively high growth in the global continuous glucose monitoring systems market with a CAGR of 16% over the forecast period. Revenue from the continuous glucose monitoring systems market in APEJ accounted for over 7% of the global continuous glucose monitoring systems market revenue in 2015. Providers of continuous glucose monitoring systems can focus on expanding across several countries in APEJ such as India and China.

Some of the key competitors in the continuous glucose monitoring systems market include Abbott, Medtronic, Dexcom, Animas, Roche, Bayer, Glysens and Ypsomed. These key players are constantly focusing on product innovation and geographical expansion to sustain their market presence and increase revenue generation by developing various types of devices and delivering outstanding offerings to several end-users.

Rising Prevalence of Diabetes and Integration of Artificial Pancreas Systems in continuous Glucose monitoring systems market

The increasing prevalence of diabetes worldwide is driving the demand for innovative and effective diabetic management devices such as continuous glucose monitoring systems. For instance, as per the International Diabetes Federation, 285 Million people worldwide suffered from diabetes in 2012; out of these, the U.S. accounted for approximately 18.8 Million cases. These facts indicate that the U.S. has high prevalence of diabetes and thus, has high market potential for continuous glucose monitoring systems.

Artificial pancreas device systems are effective in the management of diabetes. In artificial pancreas systems, continuous glucose monitoring systems technology is combined with insulin pumps in order to administer optimum dosage to manage blood-glucose levels. This will increase the demand for continuous glucose monitoring systems in the market.

For more Information @ https://www.futuremarketinsights.com/reports/continuous-glucose-monitoring-systems-market 

Key Segments Covered in the continuous glucose monitoring system Market

Component

Transmitter & monitor

Sensor

Insulin Pump

End-user

Household, and hospitals

Diagnostics Centres

Key Regions Covered

North America

Latin America

Western Europe

Eastern Europe

Japan

APEJ

Middle East & Africa

[virtualpersonmilkshake]

The Insight Partners published latest research study on "Insulin Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type [Long Acting Insulin, Rapid Acting Insulin, Short Acting Insulin & Traditional Human Insulin, Concentrated Insulin & Combination Insulin, Biosimilar Insulin, Glucagon-like peptide-1 (GLP-1), Pen & Needle, and Others] and Geography", the global insulin market size is projected to grow from $54.61 Billion in 2021 to $111.21 Billion by 2028; it is expected to grow at a CAGR of 10.8% from 2022 to 2028.

[sanyuktak]

Smart Insulin Market Share, Size and Growth Forecast, 2027

Smart Insulin or Glucose Responsive Insulin Market Outlook:

“Smart Insulin or Glucose Responsive Insulin Market: Global Opportunity Analysis and Industry Forecast, 2019–2027” Smart insulin or glucose-responsive insulin is the next generation insulin that automatically responds to changing blood glucose levels. These products help in management of blood glucose level of diabetic patients in minimally invasive manner. Smart insulin works accordingly in response to blood glucose concentration i.e. higher the blood glucose higher is the concentration of insulin released and lower the blood glucose lower is the concentration of insulin released. It is a painless mode of introducing insulin compared to injectable insulin, reducing the risk of skin irritation caused due to needles. In addition, the dose volume is easily calculated in oral & inhalable insulin and helps to maintain the dosage time. The development of smart insulin is accelerating the growth of healthcare and digital science leading to cures and treatments of patients with Type 1 and Type 2 diabetes by advance upcoming approaches.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐏𝐃𝐅 𝐁𝐨𝐮𝐜𝐡𝐞𝐫: https://www.alliedmarketresearch.com/request-sample/1674

The smart insulin or glucose responsive insulin market is segmented on the basis of type, disease, delivery devices, and region. By type, it is divided into rapid-acting, intermediate-acting, long-acting, short-acting and pre-mixed type. On the basis of disease, the market is bifurcated into Type 1 and Type 2 diabetes. On the basis of delivery devices, the smart insulin or glucose responsive insulin market is classified into smart insulin pen and smart insulin pump. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

North America accounted for the majority of the smart insulin or glucose responsive insulin market share in 2019, and is anticipated to continue this trend during the forecast period. North America holds a dominant share in the global smart insulin or glucose responsive insulin market, owing to well-developed supply-side infrastructure, rapid acceptance of innovative technologies, and adequate reimbursements (as compared to other regions).

Key Market Players

·        CeQur, Diamesco Co

·        Eli lily and Company,

·        Insulet Corporation

·        Medtronic Plc

·        Novo Nordisk A/S

·        F. Hoffmann-La Roche AG

·        Sanofi

·        Zealand Pharma

Key Advantages of the Report:

·        In detailed quantitative analysis along with the global smart insulin or glucose responsive insulin market trends

·        The smart insulin or glucose responsive insulin market size and estimations are based on a comprehensive analysis of key developments in the industry.

·        Analysis of various regions provides insights that are expected to allow companies to strategically plan their business moves. 

·        The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market.

[kingherbs]

Low GI sugar substitute and blood sugar management component innovation

Sugar is an indispensable energy substance for human body, but once excessive intake of sugar will interfere with insulin's blood sugar control, it will not only cause us to be hungry easily, the more we eat, the more obesity, and also the increase in blood sugar, leading to a large number of three high problems and even diabetes.

The purpose of sugar reduction is to reduce the increase in blood sugar. Consumers are not only reducing sugar intake, but also actively looking for clinically verified ingredients to help regulate and stabilize blood sugar levels. The following are some of the latest research and innovations in the field of blood sugar management Results.

一、Low GI sweetener

Consumers are increasingly aware of the health hazards of added sugar, which has caused a demand for a new generation of sweeteners. Some brands are turning to a new generation of sweeteners, which generally have a low glycemic index and also have other health benefits.

1. Prebiotics (inulin, oligofructose)

The functional prebiotic fibers in chicory root (such as inulin) are very suitable for use as a low GI sweetener. Both inulin and fructo-oligosaccharide from chicory root have a certain sweetness (about 30%-50%), but the calorie content is much lower than other sugars. Because it belongs to dietary fiber, compared with traditional sugar, its blood sugar response is smaller. Once it enters the body, it will not be metabolized, so it will not cause blood sugar to rise. At the same time, it can increase insulin sensitivity and reduce blood sugar through the mutual assistance of insulin, reduce the body's demand for insulin, and improve the body's sugar tolerance. In addition, both of these fibers have the additional health benefits of improving digestion. Yacon, originally produced in South America, is also a good healthy sugar substitute. Yacon syrup is 75% sweeter than sucrose, has only 1.3 calories/g, which is 1/3 of sugar, and has a GI of only 1. And the content of oligofructose is extremely high, which is 60-70% of its dry matter, and its content is the highest among all plants. These short-chain fibers have shown very ideal effects in research on weight reduction. In particular, it also contains insulin-like substances, which can help control blood sugar.

2. Palatinose

Palatinose is a low-sugar carbohydrate that can be slowly and completely digested and absorbed by the human body. It is another functional sweetener. The human body can still maintain a stable blood sugar level for more than 60 minutes after ingesting palatinose. It has great potential for blood sugar management and sports nutrition applications. 3.  A new generation of stevia

Cargill has added a new stevia sweetener to its product portfolio. Andy Ohmes, global director of high-intensity sweeteners, said that Cargill’s zero-calorie EverSweet Reb M / Reb D stevia sweetener has a smoother mouthfeel than other stevia sweeteners, and there is no aftertaste, so that it can be used alone as a whole Sugar substitute. Ohmes said: "This huge advancement in sweetener technology allows the sugar replacement rate to be as high as 100%. EverSweet contains no calories and has no effect on blood sugar levels, making it very suitable for diabetics."

4. Allulose

Allulose is another sweet ingredient, which has quickly gained popularity in the US market due to its low glycemic index. Dr. Kirstie Canene-Adams is Taylor's Global Nutrition Senior Scientist and the author of the recently published Taylor's "Innovative Ingredients for Blood Sugar Response" white paper.

Canene-Adams said that there is ample clinical evidence that allulose does not increase blood sugar or insulin levels in healthy individuals or patients with type 2 diabetes. Due to the new regulations made by the FDA in April 2019, Taylor’s Dolcia Prima brand of allulose products are exempted from the labeling requirements for "total sugar" and "added sugar", which also increases its impact on food companies attractive.

5. Coconut Flower Sugar Substitute

Coconut flower sugar was extracted from the sap of coconut flowers, coconut trees that have grown for more than 8 years can dissolve coconut nectar juice. It needs to climb to the top of the coconut trees for artificial collection, and the output of each tree is very limited every day. Usually, a coconut tree can collect 0.5~1kg of coconut flower juice every day. For every seven kilograms of coconut flower juice, about 1kg of coconut flower sugar can be made. The coconut flower juice must be refined immediately after it is collected, otherwise it will be fermented and deteriorated. The whole extraction process of coconut flower sugar is very natural, gluten-free, no additives, no preservatives, taste and color are similar to caramel, it can replace sucrose one-to-one, and is more powerful than coffee, oatmeal, cocoa, baking and other strong flavors. Fusion. The GI value of coconut flower sugar is about 35, which is a low-glycemic product (the GI value of sucrose is 65, and the GI value of glucose is 100). It is rich in vitamins, amino acids and minerals such as potassium, zinc, magnesium, and iron. The nutritional value is high, and there is no risk of gastrointestinal intolerance.

二、Blood sugar management components

1. Lemon Extract

Eriocitrin is a common glycoside in lemons, which can regulate blood sugar levels by improving insulin sensitivity. Eriomin is a lemon extract under the IBN, containing eriocidin and flavonoids. Early studies have shown that Eriomin can help maintain healthy blood sugar levels in a variety of ways, support normal insulin sensitivity, increase antioxidant activity and control inflammation.

2. Bergamot Extract

Another promising citrus ingredient is bergamot (Citrus bergamia) extract. HP Ingredients' Bergamonte complex extract Bergamonte has been shown to regulate the concentration of ghrelin and leptin hormones, and ultimately support healthy blood sugar levels. In one trial, 650 mg of Bergamonte daily reduced ghrelin levels by 6.9% after 90 days.

3. Mulberry Extract

In a randomized crossover trial, after 15 healthy volunteers consumed carbohydrates, mulberry leaf extract reduced the glycemic index of maltose, sucrose, maltodextrin and glucose. The test found that mulberry leaf extract can reduce the GI of maltose by 53% and the GI of sucrose by 33%. This preliminary trial has some limitations, such as no placebo group and small sample size, but it may lay the foundation for future research.

4. White Kidney Bean Extract

White kidney bean extract is an α-amylase inhibitor, which can inhibit the activity of α-amylase and block the decomposition of starch, so that the starch cannot be digested and absorbed by the human body. At present, white kidney bean extract is widely used in foods that regulate blood sugar, and these foods can also be eaten as ordinary foods. After the white kidney bean extract enters the intestine to exert its effect, it will be excreted quickly, without entering the blood circulation, nor acting on the brain center, without side effects.

5. Bitter Melon Extract

Bittermelon contains steroidal saponins known as charantin, insulin-like peptides and alkaloids, which gives it hypoglycemic ability. Charantin stimulates the release of insulin and blocks the formation of glucose in the bloodstream, which may be helpful in the treatment of diabetes particularly in non-insulin dependent diabetes. The hypoglycemic effect is attributed to two factors:

(1)Charantin- a crystalline fraction obtained from an alcoholic extract of the fruit. Charantin administered at a 50mg/kg dose reduced hyperglycemia in rabbits by 42%. Charantin posesses pancreatic and extra-pancreatic action, and has a slight antispasmodic and anticholinergic effect.

(2)P-isulin (or v-insulin, for vegetable insulin). This is a large polypeptide structurally and pharmacologically comparable to bovine insulin. The p-insulin is composed of two polypeptide chains bound together by disulphide bonds. Subcutaneous and intramuscular administration of p-insulin produced hypoglysemic effects in diabetic patients, the peak effect was observed after 4-8 hours as compared to 2 hours for bovine insulin.

6. Chromium can promote sugar metabolism

Chromium picolinate can improve blood sugar metabolism and carbohydrate metabolism, while increasing insulin sensitivity. A literature report in 2018 concluded that chromium picolinate helps to lose weight while maintaining weight. Another randomized placebo-controlled trial found that chromium improved markers of oxidative stress in diabetic patients.

三、Other blood sugar management components

Tomato extract, Broccoli extract, Bilberry extract, Fenugreek seed extract, Ginseng extract, Angelica root extract, Pumpkin extract, Kudzu root extract, Aloe vera extract, Garlic extract, Onion extract.

article from:https://www.kingherbs.com/info/low-gi-sugar-substitute-and-blood-sugar-manage-61237981.html